FBLG — Fibrobiologics Cashflow Statement
0.000.00%
Last trade - 00:00
- $163.27m
- $155.57m
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Net Income/Starting Line | -1.58 | -5.12 | -16.5 |
Depreciation | |||
Non-Cash Items | — | 0.748 | 9.54 |
Other Non-Cash Items | |||
Changes in Working Capital | 0.172 | 0.307 | 0.493 |
Change in Prepaid Expenses | |||
Change in Other Assets | |||
Change in Accrued Expenses | |||
Change in Payable / Accrued Expenses | |||
Change in Other Liabilities | |||
Cash from Operating Activities | -1.41 | -4.07 | -6.4 |
Capital Expenditures | — | — | -0.495 |
Purchase of Fixed Assets | |||
Cash from Investing Activities | — | — | -0.495 |
Financing Cash Flow Items | 0.292 | — | -2.65 |
Other Financing Cash Flow | |||
Net Issuance / Retirement of Stock | |||
Net Issuance / Retirement of Debt | |||
Cash from Financing Activities | 1.82 | 5.92 | 13.8 |
Beginning Cash Balance | |||
Ending Cash Balance | |||
Net Change in Cash | 0.407 | 1.86 | 6.9 |